Literature DB >> 21621811

Synthesis and biological activity of derivatives of tetrahydroacridine as acetylcholinesterase inhibitors.

Paweł Szymański1, Magdalena Markowicz, Elżbieta Mikiciuk-Olasik.   

Abstract

Current state of medical sciences does not allow to treatment neurodegenerative diseases such as Alzheimer's disease (AD). At present treatment of AD is severely restricted. The main class of medicines which are applied in AD is acetylcholinesterase inhibitors (AChEIs) like tacrine, donepezil, galantamine and rivastigmine that do not contribute to significant and long-term improvement in cognitive and behavioural functions. In this work, we report synthesis and biological evaluation of new hybrids of tacrine-6-hydrazinonicotinamide. The synthesis was based on the condensation reaction between tacrine derivatives and the hydrazine nicotinate moiety (HYNIC). All obtained compounds present affinity for both cholinesterases and are characterized by high selectivity in relation to butyrylcholinesterase (BChE).
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621811     DOI: 10.1016/j.bioorg.2011.05.001

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  7 in total

1.  Novel Cyclopentaquinoline and Acridine Analogs as Multifunctional, Potent Drug Candidates in Alzheimer's Disease.

Authors:  Karolina Maciejewska; Kamila Czarnecka; Paweł Kręcisz; Dorota Niedziałek; Grzegorz Wieczorek; Robert Skibiński; Paweł Szymański
Journal:  Int J Mol Sci       Date:  2022-05-24       Impact factor: 6.208

2.  New cyclopentaquinoline hybrids with multifunctional capacities for the treatment of Alzheimer's disease.

Authors:  Kamila Czarnecka; Małgorzata Girek; Karolina Maciejewska; Robert Skibiński; Jakub Jończyk; Marek Bajda; Jacek Kabziński; Przemysław Sołowiej; Ireneusz Majsterek; Paweł Szymański
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

3.  Design, Synthesis and Bioactivity Evaluation of Coumarin-BMT Hybrids as New Acetylcholinesterase Inhibitors.

Authors:  Fanxin Zeng; Tao Lu; Jie Wang; Xuliang Nie; Wanming Xiong; Zhongping Yin; Dayong Peng
Journal:  Molecules       Date:  2022-03-26       Impact factor: 4.411

4.  New Imaging Modality of COVID-19 Pneumonia Developed on the Basis of Alzheimer's Disease Research.

Authors:  Przemysław Koźmiński; Dorota Niedziałek; Grzegorz Wieczorek; Paweł K Halik; Kamila Czarnecka; Aleksandra Rogut; Łukasz Cheda; Zbigniew Rogulski; Paweł Szymański; Ewa Gniazdowska
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

5.  2,3-dihydro-1H-cyclopenta[b]quinoline derivatives as acetylcholinesterase inhibitors-synthesis, radiolabeling and biodistribution.

Authors:  Paweł Szymański; Alice Lázničková; Milan Lázniček; Marek Bajda; Barbara Malawska; Magdalena Markowicz; Elżbieta Mikiciuk-Olasik
Journal:  Int J Mol Sci       Date:  2012-08-13       Impact factor: 6.208

6.  New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer's Disease.

Authors:  Kamila Czarnecka; Małgorzata Girek; Przemysław Wójtowicz; Paweł Kręcisz; Robert Skibiński; Jakub Jończyk; Kamil Łątka; Marek Bajda; Anna Walczak; Grzegorz Galita; Jacek Kabziński; Ireneusz Majsterek; Piotr Szymczyk; Paweł Szymański
Journal:  Int J Mol Sci       Date:  2020-05-26       Impact factor: 5.923

Review 7.  A review of the mechanisms underlying selected comorbidities in Alzheimer's disease.

Authors:  Karolina Maciejewska; Kamila Czarnecka; Paweł Szymański
Journal:  Pharmacol Rep       Date:  2021-06-13       Impact factor: 3.024

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.